Bristol-Myers Squibb

Q32 Bio Launches with $46 Million and IL-7 Inhibitor Licensed from BMS
BioSpace
Wed, 05/27/20 - 11:55 pm
Q32 Bio
Bristol-Myers Squibb
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
Pharmaceutical Business Review
Wed, 05/27/20 - 10:30 am
Bristol-Myers Squibb
Opdvio
Yervoy
metastatic non-small cell lung cancer
Bristol Myers snags Pomalyst green light in rare AIDS-related skin lesions
Fierce Pharma
Sat, 05/16/20 - 11:58 am
Bristol-Myers Squibb
Pomalyst
AIDS
FDA
Kaposi's Sarcoma
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Thu, 05/14/20 - 10:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
ASCO 2020 – first-line lung cancer focus
EP Vantage
Thu, 05/14/20 - 12:02 pm
Roche
Merck
Bristol-Myers Squibb
ASCO 2020
lung cancer
Keytruda
tiragolumab
Opdivo
Yervoy
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Motley Fool
Wed, 05/13/20 - 11:21 am
Bristol-Myers Squibb
Bluebird Bio
refusal to file letter
FDA
ide-cel
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Motley Fool
Mon, 05/11/20 - 11:36 pm
Bristol-Myers Squibb
Celgene
M&A
Bluebird Bio
Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs
Xconomy
Fri, 05/8/20 - 10:30 am
Ayala Pharmaceuticals
IPOs
cancer
Bristol-Myers Squibb
3 Reasons Bristol Myers Squibb's Revenue Skyrocketed in Q1
Motley Fool
Thu, 05/7/20 - 11:03 am
Bristol-Myers Squibb
earnings
From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
Motley Fool
Thu, 05/7/20 - 10:46 am
FDA
drug approvals
Gilead Sciences
remdesivir
AstraZeneca
Merck
Lynparza
Clovis Oncology
Rubraca
Bristol-Myers Squibb
Opdivo
Yervoy
Another delay for Bristol Myers cell therapy as FDA extends review
BioPharma Dive
Wed, 05/6/20 - 12:21 pm
FDA
Bristol-Myers Squibb
liso-cell
cancer
cell therapy
CHMP backs BMS’ first-in-class anemia drug Reblozyl
Pharmaforum
Mon, 05/4/20 - 10:34 am
Bristol-Myers Squibb
EMA
CHMP
Reblozyl
anemia
Celgene
Go or no go? Oncology dominates upcoming decisions
EP Vantage
Fri, 05/1/20 - 11:09 am
FDA
oncology
AstraZeneca
Lynparza
ovarian cancer
prostate cancer
Bristol-Myers Squibb
Opdivo
lung cancer
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Mon, 04/20/20 - 11:59 pm
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
Intensity Therapeutics signs clinical collaboration agreement with Bristol Myers Squibb for advanced solid tumors
Pharmaceutical Business Review
Wed, 04/15/20 - 10:47 am
Bristol-Myers Squibb
Intensity Therapeutics
INT230-6
Yervoy
solid tumors
Calling Gilead's CAR-T infringement 'willful,' judge enhances BMS' award to $1.2B
Fierce Pharma
Fri, 04/10/20 - 10:23 am
Gilead Sciences
CAR-T
patents
Bristol-Myers Squibb
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
Fierce Pharma
Wed, 04/8/20 - 11:40 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
Europe
priority review
EMA
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Pharmaceutical Business Review
Mon, 04/6/20 - 10:30 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
MDS
Bristol Myers to CEO Caforio: Good job on Celgene so far, but you'll have to work for your raise
Fierce Pharma
Thu, 04/2/20 - 12:00 am
Bristol-Myers Squibb
Celgene
executive pay
Giovanni Caforio
COVID-19 prompts Pfizer to stop enrollment in most studies
Fierce Pharma
Thu, 03/26/20 - 10:33 am
Pfizer
Bristol-Myers Squibb
Eli Lilly
R&D
clinical trials
COVID-19

Pages